Paget's Disease: Diagnosis, Management, and Insights into the Breast (PDB)
Paget's disease of the breast is a rare kind of breast cancer that mostly affects the skin around the nipple. It happens in only a small number of breast cancer cases because it's linked to certain gene changes and other types of breast tumors. Doctors notice it more in women who have stopped having periods (postmenopausal women). Things like what you eat, where you live, and how often you get check-ups can change your chances of having this disease.
Paget's disease of the breast is found more often in countries like the United States and those in Western Europe, compared to places in Asia. This could be because people in those countries have more access to doctors, tests, and information about breast health. Even though this disease is not very common, it's important to pay attention to it because it can be connected to other serious breast tumors. Catching and treating it early helps people have better results and stay healthier in the long run.
Table of Contents:
Paget's disease of the breast is a rare breast cancer that affects the skin of the nipple and sometimes the areola. It is characterized by a rash or eczema like appearance on the nipple and areola which can be accompanied by itching, redness and discharge. It is often associated with an underlying breast cancer which can be invasive or non-invasive (ductal carcinoma in situ, DCIS). Paget's disease of the breast is named after Sir James Paget, a 19th century British doctor who first described the condition.
The pathogenesis of PDB is explained by two theories:
The first theory is the epidermotropic theory which suggests that Paget cells come from an underlying ductal carcinoma in situ (DCIS) or invasive breast carcinoma. These cells retain their malignant properties and contribute to the histopathological findings of Paget's disease. These cancer cells are thought to migrate from an underlying carcinoma through the lactiferous ducts to the nipple epidermis.
The second theory is the in situ transformation theory which suggests that Paget cells arise as a primary intraepidermal malignancy independent of any underlying breast carcinoma. This theory is supported by cases where no underlying breast tumor is found.
Epidermotropic Theory: This is the most widely accepted theory which suggests that malignant ductal cells migrate from an underlying carcinoma through the lactiferous ducts to the epidermis of the nipple. These cells retain their malignant properties and contribute to the histopathological findings of Paget's disease. This theory is supported by the frequent finding of underlying DCIS or invasive carcinoma in patients with PDB. In some cases this underlying carcinoma can be an invasive breast cancer which affects the prognosis and treatment.
In Situ Transformation Theory: This is an alternative theory which suggests that malignant cells arise de novo within the epidermis of the nipple possibly due to local field effects or genetic mutations. Although this theory is less accepted, it highlights the complexity of the disease. Further research is needed to understand the molecular mechanisms.
Characteristic features are large, pale, vacuolated Paget cells in the epidermis often with HER2 overexpression. The strong association with DCIS or invasive carcinoma emphasizes the need for full evaluation. [2] Recent studies have looked at molecular pathways including HER2 signaling and immune evasion mechanisms as potential targets for treatment. For example HER2 targeted therapy like trastuzumab has shown promise in improving outcomes.
Paget's disease of the breast is a rare condition and accounts for about 1-4% of all breast cancer. The exact cause of Paget's disease is not known but it is associated with underlying breast cancer. The risk factors for Paget's disease are similar to breast cancer:
Knowing these risk factors is important for early detection and prevention. Regular screenings and genetic counseling can help identify those at higher risk and can be managed proactively. [4]
PDB usually presents with changes in the nipple-areola complex:
Unilateral symptoms are common but bilateral symptoms are rare and should prompt consideration of other diagnoses. Symptom progression varies; early cases may present with subtle scaling and advanced cases may have ulceration and nipple destruction. Recognizing these stages is important for timely interventions. Case studies show that early detection of these subtle signs can improve prognosis.
Diagnosis of PDB is a combination of clinical evaluation, imaging and histopathological assessment. If an underlying cancer is suspected, a sentinel lymph node biopsy may be done to assess the spread of cancer to the axillary lymph nodes. [5]
A comparison of imaging modalities shows that MRI is more sensitive than mammography and ultrasound especially in younger patients or those with dense breasts. However, the cost and false positive results should be considered. Advanced techniques like diffusion-weighted imaging (DWI) and contrast-enhanced mammography are emerging as promising tools to improve diagnostic accuracy.
Immunohistochemistry: HER2 is overexpressed in 80-100% of cases, ER and PR status varies depending on the underlying cancer. Advances in molecular diagnostics including next-generation sequencing is helping us understand the genetic basis of PDB. For example, TP53 and PIK3CA mutations have been linked to disease progression and potential targets for therapy.
Treatment of PDB depends on the extent of disease and presence of underlying cancer. Treatment options are surgery, radiation and systemic therapy.
Radiation Therapy: Reduces local recurrence, especially after BCS. Whole breast radiation therapy is usually recommended after BCS to make sure any remaining cancer cells are killed and reduce the risk of recurrence.
Oncoplastic surgery has improved the cosmetic outcome for BCS patients. Nipple-sparing mastectomy is also becoming popular, balancing oncological safety and aesthetic preservation. 3D imaging and intraoperative margin assessment has further improved surgical precision.
Emerging therapies like antibody-drug conjugates (e.g. trastuzumab deruxtecan) and immune checkpoint inhibitors are being studied in clinical trials and may add to the treatment options for PDB. Combination therapy targeting both HER2 and PD-1/PD-L1 are showing promising results in early phase trials and may be the future of personalized medicine.
Prognosis of Paget's disease of the breast depends on the underlying cancer and stage of the disease. If the underlying cancer is non-invasive (DCIS), prognosis is good, 5 year survival is over 90%. If the underlying cancer is invasive, prognosis is poor, 5 year survival is 50-60%. Prognosis is poorer if the cancer has spread to the nodes or other parts of the body.
Early detection and comprehensive treatment is key to better outcomes. Advances in imaging and targeted therapy has improved the management of Paget's disease and hope for better survival and quality of life.
In peripartum women presenting with nipple-areola complex changes, PDB should be included in the differential diagnosis. PDB is often associated with tumors in the same breast tissue so it is important to evaluate the same breast for any underlying tumors. Diagnostic delays are common because PDB looks like benign conditions.
Multidisciplinary management is important to balance maternal and fetal well being while ensuring prompt treatment [2]. Case reports have shown the challenges of managing PDB during pregnancy and the importance of individualized care plan. Imaging modalities like ultrasound which is non-ionizing radiation is preferred during pregnancy.
Modern Treatment TrendsBreast conserving approach is the trend now with improvements in imaging, surgery and adjuvant therapy. Personalized treatment plan based on tumor biology and patient preference has resulted to better functional and cosmetic outcome. AI is also being integrated in imaging and pathology to aid in earlier detection and more accurate diagnosis of PDB.
Patient education and awareness is key in the diagnosis and treatment of Paget's disease of the breast. Women should be aware of the signs and symptoms of Paget's disease, a rash or eczema like appearance on the nipple and areola, itching, redness and discharge. Women should also be aware of their risk for breast cancer and take steps to reduce their risk, get regular mammograms and do breast self exam.
Educational campaigns and resources can help women to seek medical attention if they notice any changes in their breast tissue. Early intervention can make a big difference in prognosis and treatment outcome.
Multidisciplinary approach is important in the diagnosis and treatment of Paget's disease of the breast. A team of healthcare professionals including breast surgeon, medical oncologist, radiation oncologist and pathologist should work together to develop a treatment plan that is individualized to the patient. Treatment may include surgery, radiation therapy, chemotherapy and hormone therapy depending on the underlying cancer and stage of the disease.
Team work among specialists ensures comprehensive care of all aspects of the disease. This team based approach not only improves clinical outcome but also the overall well being of the patient and provide holistic treatment experience.
Paget's disease of the breast is a rare but significant malignancy that requires high index of suspicion for early diagnosis. Mammary Paget disease which involves the nipple-areola complex requires thorough understanding of its clinical presentation and underlying pathology.
Advances in imaging, histopathology and systemic therapy has improved diagnostic accuracy and treatment outcome. Breast conserving surgery when possible is a trend towards less invasive management which is patient centered.
Future research should focus on the molecular mechanism of PDB and identification of new therapeutic targets to further improve outcome. Development of AI driven diagnostic tool and precision therapy will be the game changer in PDB management in the coming years.
[1] Hudson-Phillips, S., Cox, K., Patel, P., & Al Sarakbi, W. (2023). Paget's disease of the breast: diagnosis and management. British journal of hospital medicine (London, England : 2005), 84(1), 1–8. https://doi.org/10.12968/hmed.2022.0439
[2] Gilmore, R., Prasath, V., & Habibi, M. (2020). Paget Disease of the Breast in Pregnancy and Lactation. Advances in experimental medicine and biology, 1252, 133–136. https://doi.org/10.1007/978-3-030-41596-9_18
[3] Karakas C. (2011). Paget's disease of the breast. Journal of carcinogenesis, 10, 31. https://doi.org/10.4103/1477-3163.90676
[4] Dalton, J. C., & Plichta, J. K. (2024). Paget's disease of the breast: Insights from imaging to guide surgical management. American journal of surgery, 231, 16–17. https://doi.org/10.1016/j.amjsurg.2024.03.013
[5] Sakorafas, G. H., Blanchard, K., Sarr, M. G., & Farley, D. R. (2001). Paget's disease of the breast. Cancer treatment reviews, 27(1), 9–18. https://doi.org/10.1053/ctrv.2000.0203
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
4 hours ago
- UPI
Childhood trauma linked to higher risk of endometriosis in adult women
1 of 2 | Endometriosis affects one in 10 women in the United States and can cause chronic and frequently severe pelvic pain. A new study has found that women who experienced childhood traumas are at heightened risk to develop the condition as adults. Photo by cottonbro studio/ Pexels ST. PAUL, Minn., June 11 (UPI) -- A suspected link between childhood trauma and the risk of developing endometriosis in later life was strengthened Wednesday with the publication of study that showed a greater chance of the condition among women with histories of difficult childhoods. The study of hundreds of thousands of women in Sweden found those who as children experienced substance abuse, had a teenage or mentally ill parent, financial problems or a death in the family were linked to a 20% increased risk of an endometriosis diagnosis compared to women who had not been exposed. However, the risk was much greater for girls exposed more than one of those factors, rising to 60%, while those who witnessed or were subjected to violence saw more than twice the risk of developing endometriosis later in life compared to women who had not been exposed, the Swedish authors reported. The study published in the British medical journal Human Reproduction builds on earlier findings that women who experienced physical and sexual abuse as children had a 79% higher risk of developing the painful condition, which affects one in 10 reproductive-age women in the United States. Lead author Dr. Marika Rostvall, a physician and doctoral student in the Department of Global Public Health at the Karolinska Institute in Stockholm, told UPI the findings provide more evidence of the strong connection between mental and physical health. The findings "support previous studies in other areas of medicine suggesting that the mind and body are intimately connected and that psychologically taxing events can have biological consequences," she said in emailed comments. Endometriosis usually affects women in their 20s and 30s, and while there are a handful known risk factors such as starting menstruation early and having a lean body type, the cause remains unknown. The problems stem from the behavior of tissues known as endometrium, which under normal circumstances are found only in the inner lining of a woman's uterus. Those tissues grow to a thick, blood vessel-rich layer during the menstrual cycle to prepare for possible implantation of an embryo, and then shed the blood at the end of the cycle if there is no embryo present. But in some cases, endometrium behave abnormally and start growing outside of the uterus. When they do so, they can attach themselves to the ovaries, fallopian tubes, bowel, bladder or other parts of the body, triggering frequently severe pelvic pain as they carry out their monthly thickening function. As a result, endometriosis can cause excessive bleeding and even infertility -- which is the case for up to half of women with the condition -- as well as cysts, scar tissue and adhesions. Those in turn can trigger chronic pain, including during with sexual intercourse as well as during urination or bowel movements. The Swedish researchers began by looking at the health records of more 1.3 million women born in in the country between 1974 and 2001, eventually narrowing it down to 24,000 who were diagnosed with endometriosis. They then tapped several national registers to track their childhood experiences, looking for evidence of trauma or difficulties, including crimes such as violence and sexual abuse. The results, they said, demonstrate the importance of considering "the whole person" not just the symptoms of endometriosis. The negative physical consequences of psychological trauma can perhaps be traced to a compromised ability of the immune system to protect against the condition, or even in how the body perceives pain, Rostvall said. "I think the immune system is an interesting part of the puzzle when it comes to trying to understand why some women develop endometriosis," she said. "Chronic inflammation is a big part of the disease, and it has also been shown that women with endometriosis have a higher incidence of autoimmune disorders compared to healthy women. "There is a lot of interesting research being done in the area, and a deeper understanding of exactly how the immune system functions in relation to endometriosis could potentially help bring forward new kinds of treatment." Like some other women's health issues, the pain of endometriosis is often dismissed and sufferers have reported negative experiences with healthcare professionals, often in the form of providers "trivializing" symptoms, which can cause feelings of loneliness and alienation. This, in turn, can make obtaining a diagnosis difficult and prompt some to choose to avoid engaging with doctors altogether. A British psychological-based study from last year showed some women who suffered symptoms felt they had experienced a form of "medical gaslighting" in which they were made to doubt their own perceptions of pain. Rostvall said these kinds of experiences are especially relevant when the patients are women who come from socially and psychologically traumatic backgrounds. "A lot of women presenting with pain, especially socioeconomically disadvantaged women and women with psychiatric comorbidities, who are more likely to have experienced childhood adversity, have their pain dismissed. They then have to wait for a long time to receive a diagnosis and treatment, potentially allowing the condition to worsen," she said. "I think physicians should be aware of the complex linkage between the mind and body in general and be more open to listening to their patients' stories, take their pain seriously, and offer a thorough physical examination."
Boston Globe
21 hours ago
- Boston Globe
Jillian Sackler, philanthropist who defended husband's legacy, dies at 84
Arthur Sackler died in 1987 — nine years before the opioid OxyContin was marketed by the company as a powerful painkiller. Shortly after his death, his estate sold his share of the company to his billionaire brothers, Raymond and Mortimer, for $22.4 million. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up The company's misleading advertising claim that OxyContin was nonaddictive prompted doctors to overprescribe it beginning in the 1990s. The proliferation of the medication ruined countless lives of people who became dependent on it. Advertisement In 2021, the company proposed a bankruptcy settlement in which members of the Sackler family agreed to pay $4.2 billion over nine years to resolve civil claims related to the opioid crisis. In return, they sought immunity from future lawsuits. In 2024, the US Supreme Court struck down that deal. A revised settlement was reached in 2025, with the Sacklers and Purdue agreeing to pay $7.4 billion without receiving immunity. The first payment, within three years, included $1.5 billion from the Sacklers and nearly $900 million from Purdue. Advertisement But the backlash from the crisis prompted universities and cultural institutions — including the Louvre and the Metropolitan Museum of Art — to obliterate the Sackler name from programs, buildings, and galleries, and to declare that they would no longer accept any philanthropy from the family. Jillian Sackler — a British native who was made a dame by Queen Elizabeth II in 2005 for her philanthropic work — mounted a concerted publicity campaign to absolve her husband of any complicity or culpability, repeatedly reminding the public that he had died long before the scandal erupted. While she stopped short of saying that the drug was the 'root cause' of the opioid crisis, she accused the company of misleading advertising. She told The Guardian that the other members of the family 'have a moral duty to help make this right and to atone for any mistakes made.' As for Arthur, she added: 'I think he would not have approved of the widespread sale of OxyContin.' The couple were avid art collectors and patrons. One art scholar described Arthur Sackler as 'a modern Medici.' The couple was associated with major cultural and academic institutions like the Arthur M. Sackler Gallery at the Smithsonian Institution; the Sackler Wing at the Metropolitan Museum; the Arthur M. Sackler Museum at Harvard University (now part of the Harvard Art Museums); the Arthur M. Sackler Sciences Center at Clark University; and the Arthur M. Sackler Center for Health Communications and the Sackler School of Graduate Biomedical Sciences, both at Tufts University. After Arthur Sackler died, his wife continued his philanthropic agenda. Donations from his estate and insurance benefits helped finance the Jillian and Arthur M. Sackler Wing of Galleries at the Royal Academy of Arts in London, the Arthur M. Sackler Museum of Art and Archaeology at Peking University, the Arthur M. Sackler Colloquia at the National Academy of Sciences, and Studio International, an art magazine. Their name was removed from some, but not all, of those institutions. Advertisement Gillian Lesley Tully was born on Nov. 17, 1940, in Stoke-on-Trent, in central England south of Manchester. She changed the spelling of her first name when she moved to the United States to be with Arthur Sackler, whom she met in 1967 when he was visiting London; they married in 1980. Her father, Kenneth Tully, worked at Midland Bank (now HSBC UK). He married a colleague, Doris Queenie-Gillman Smith. Ms. Sackler had a younger brother, Brian Tully, who died in 2019, leaving her no immediate survivors except for Arthur Sackler's children from an earlier marriage. Among them is Elizabeth Sackler, a philanthropist who has described the estimated $13 billion amassed by her aunts and cousins during the opioid crisis as 'morally abhorrent.' Jillian Sackler attended New York University. The couple moved into a home on Park Avenue in Manhattan, where she continued to live after her husband's death. In her role as president and CEO of the Dame Jillian and Dr. Arthur M. Sackler Foundation for the Arts, Sciences and Humanities, Sackler referred to the other branches of her husband's family as the 'OxySacklers.' In an opinion piece in The Washington Post in 2019, she wrote that her husband had been smeared through 'guilt by association.' Advertisement 'Neither Arthur nor his heirs had anything to do with the manufacture or marketing of OxyContin,' she asserted. 'Suggestions that his philanthropy is now somehow tainted are simply false.' She added: 'Arthur is not here to answer back, but I can tell you that blaming him for OxyContin's marketing, or for any other wrongdoing by the pharmaceutical industry, is as ludicrous as blaming the inventor of the mimeograph for email spam.' This article originally appeared in
Yahoo
a day ago
- Yahoo
L'Oréal to acquire majority stake in British skincare brand Medik8
L'Oréal Group has signed an agreement to acquire a majority stake in UK-based skincare brand Medik8. Inflexion, a European mid-market private equity company, will retain a minority share post-transaction. The acquisition is a strategic move by L'Oréal to bolster its Luxe division with a brand that has a strong foundation in scientific research and innovation. Medik8's performance and potential for international expansion make it a valuable addition to L'Oréal's portfolio. L'Oréal will begin to consolidate Medik8's sales following the transaction's closure. The agreement grants L'Oréal rights to eventually acquire the remaining shares held by minority shareholders. L'Oréal LUXE president Cyril Chapuy stated: 'We are delighted to welcome Medik8 to the L'Oréal family. As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio. 'We share a strong belief in Medik8's global potential and are excited to embark on this journey together, to build a powerful and impactful brand presence worldwide.' Completion of the transaction is anticipated in the summer or early autumn of 2025, pending regulatory approvals. Founded by scientist Elliot Isaacs, Medik8 is known for its CSA Philosophy: Vitamin C plus Sunscreen by day, Vitamin A by night. Medik8's has expanded its omni-channel sales strategy to include major online and offline retailers in Europe and the US. Medik8 CEO Simon Coble stated: 'I am delighted to be joining forces with a company which shares our vision for the brand's future growth and whose core values align with our deep commitment to science, innovation and above all, results without compromise. I look forward to the next stage in Medik8's journey, as we work together to bring our innovative products to a wider audience.' "L'Oréal to acquire majority stake in British skincare brand Medik8" was originally created and published by Retail Insight Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
